Do inflammatory cytokines suppress GnRH and LH to lower testosterone production?

The interaction between the immune system and the endocrine system is a well-established mechanism whereby systemic inflammation can lead to secondary hypogonadism. Research confirms that inflammatory cytokines act at every level of the hypothalamic-pituitary-gonadal (HPG) axis to downregulate testosterone production.

Clinical and mechanistic evidence

The suppression of the male reproductive axis during inflammatory states—such as chronic infection, obesity, or aging—is driven by several convergent pathways:

• Hypothalamic GnRH Suppression: Pro-inflammatory cytokines, specifically Tumor Necrosis Factor-alpha (TNF-α) and Interleukin-1 beta (IL-1β), directly impair the pulsatile release of Gonadotropin-Releasing Hormone (GnRH). This occurs largely through the disruption of kisspeptin neurons, which are the essential upstream regulators of GnRH. Studies show TNF-α impairs human fetal GnRH neuron function, while IL-1β downregulates GnRH secretion independently of pituitary activity.
• Pituitary LH Inhibition: Cytokines also exert direct inhibitory effects on the anterior pituitary. IL-1β binds to receptors on pituitary gonadotrope cells, reducing the expression of the LHβ gene. This suppresses Luteinizing Hormone (LH) release even when GnRH is present, effectively blunting the pituitary's responsiveness.
• Reduced Testicular Steroidogenesis: Because LH is the primary stimulus for the Leydig cells in the testes, its reduction lead to a proportional drop in testosterone production. Mechanistically, this happens because lower LH levels fail to activate the Steroidogenic Acute Regulatory (StAR) protein and key enzymes (CYP11A1, CYP17A1) required to convert cholesterol into testosterone.

Safety and clinical implications

While inflammation-induced testosterone suppression is often reversible if the underlying inflammatory trigger is resolved, chronic states can lead to persistent hypogonadotropic hypogonadism. In men (particularly those in the 40+ age demographic), this manifests as low testosterone levels accompanied by "inappropriately normal" or low LH levels, rather than the elevated LH levels seen in primary testicular failure.

Bottom line

The claim is strongly supported by science. Inflammatory cytokines like TNF-α and IL-1β suppress hypothalamic GnRH pulsatility and direct pituitary LH secretion, removing the necessary signal for Leydig cells to produce testosterone. This dual-level inhibition is a primary driver of secondary hypogonadism in inflammatory disease states.